文献速递糖尿病

非奈利酮在2型糖尿病中的疗效与安全性:心力衰竭与慢性肾脏病试验的汇总分析

Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials of Heart Failure and Chronic Kidney Disease.
PubMed 文献 · Diabetes Care · 2025-01-01

该研究为FINE-HEART预设的参与者水平汇总分析,纳入18,991例参与者中15,365例(80.9%)有2型糖尿病且基线HbA1c可用者,评估非奈利酮对比安慰剂对心血管死亡等结局的影响。中位随访2.9年,非奈利酮对比安慰剂对心血管死亡的治疗效应在基线HbA1c(交互作用P=0.75)和降糖治疗方案(交互作用P=0.46)间一致,并一致降低肾脏复合结局、心衰住院、主要不良心血管事件和全因死亡率。

要点

  • 非奈利酮对比安慰剂对心血管死亡的治疗效应在基线HbA1c间一致(交互作用P=0.75)。
  • 非奈利酮对比安慰剂对心血管死亡的治疗效应在降糖治疗方案间一致(交互作用P=0.46)。
  • 非奈利酮一致降低肾脏复合结局、心衰住院、主要不良心血管事件和全因死亡率。

核心结论

  • 非奈利酮在广泛的血糖水平和降糖方案范围内一致降低2型糖尿病患者的发病率和死亡率。

研究设计与样本

  • FINE-HEART为预设的参与者水平汇总分析,纳入迄今为止所有评估非奈利酮对比安慰剂的III期临床试验。
  • 18,991例FINE-HEART参与者中15,365例(80.9%)有2型糖尿病且基线HbA1c可用,平均年龄66±10岁,女性占32%,平均HbA1c为7.6±1.4%。
  • 采用分层Cox比例风险模型,按基线HbA1c和降糖治疗方案评估治疗效应。

主要发现

  • 中位随访2.9年,非奈利酮对比安慰剂对心血管死亡的治疗效应在基线HbA1c间一致(交互作用P=0.75)。
  • 非奈利酮对比安慰剂对心血管死亡的治疗效应在降糖治疗方案间一致(交互作用P=0.46)。
  • 无论基线HbA1c和降糖治疗方案如何,非奈利酮一致降低肾脏复合结局、心衰住院、主要不良心血管事件和全因死亡率。
  • 非奈利酮的治疗效应在背景降糖治疗数量间一致,且与是否联用SGLT2i或GLP-1RA无关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and safety of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in individuals with type 2 diabetes (T2D) and either chronic kidney disease (CKD) or heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF). RESEARCH DESIGN AND METHODS: In this prespecified participant-level pooled analysis of all phase III clinical trials evaluating finerenone versus placebo conducted to date (FINE-HEART), the safety and efficacy of finerenone was evaluated among participants with a history of T2D. Treatment effects on the primary outcome of cardiovascular death and other secondary outcomes were evaluated according to baseline glycated hemoglobin (HbA1c) and glucose-lowering therapy (GLT) regimen using stratified Cox proportional hazards models. RESULTS: Of 18,991 FINE-HEART participants, 15,365 (80.9%) had T2D and available HbA1c at baseline (mean age, 66 ± 10 years; 32% women; mean HbA1c, 7.6 ± 1.4%). The most common GLT regimens were insulin alone (n = 2,652), insulin and metformin (n = 2,005), metformin alone (n = 1,616), metformin and sulfonylurea (n = 1,039), and "other" (n = 8,117), including sodium-glucose cotransporter 2 inhibitor (SGLT2i) and glucagon-like peptide 1 receptor agonist (GLP-1RA). Over a median follow-up of 2.9 years, treatment effects of finerenone versus placebo on cardiovascular death were consistent across baseline HbA1c (Pinteraction = 0.75) and GLT regimen (Pinteraction = 0.46). Finerenone consistently reduced the kidney composite outcome, HF hospitalization, major adverse cardiovascular events, and all-cause mortality, irrespective of baseline HbA1c and GLT regimen. Treatment effects of finerenone were also consistent across number of background GLTs and irrespective of concomitant treatment with a SGLT2i or GLP-1RA. CONCLUSIONS: Finerenone consistently reduced morbidity and mortality in individuals with T2D across a broad range of glycemia and glucose-lowering regimens.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Ostrominski JW, Claggett BL, Miao ZM, et al. Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials of Heart Failure and Chronic Kidney Disease. Diabetes Care. 2025. PMID: 40019856. doi:10.2337/dc24-1873

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。